Table 3 Characteristics of the patients of the Radboudumc
|  | All patients (n = 57) | No NIV indication (n = 35, 61.4%) | NIV indication (n = 22, 38.6%) | P-value |
|---|---|---|---|---|
Demographic and disease variables | ||||
 Male (%) | 50.9 | 54.3 | 45.5 | 0.516 |
 Diagnosis ALS/PMA (% ALS) | 87.7 | 88.6 | 86.4 | 0.805 |
 Onset Spinal/Bulbar/Both (%) | 45.6 / 36.8 / 17.5 | 40.0 / 37.1 / 22.9 | 54.5 / 36.4 / 9.1 | 0.352 |
 Age at referral (years) | 64.6 ± 12.7 | 61.4 ± 13.1 | 69.8 ± 10.3 | 0.014 |
 Disease duration (years) | 1.9 ± 1.6 | 2.0 ± 1.6 | 1.8 ± 1.8 | 0.572 |
 Deceased (n) | 34 | 19 | 15 | 0.298 |
Variables at HVS | ||||
 Interval referral and first assessment (weeks) | 5.6 ± 5.1 | 6.6 ± 5.9 | 4.1 ± 2.9 | 0.056 |
 pCO2 at first evaluation (mmHg) | 40.6 ± 6.3 | 37.92 ± 3.19 | 44.95 ± 7.70 | <0.0001 |
 Bicarbonate at first evaluation (mmol/L) | 26.7 ± 3.7 | 25.08 ± 2.51 | 29.23 ± 3.88 | <0.0001 |
 Follow up until NIV (months)* | 12 ± 6 | 12 ± 6 | 0 ± 0 | - |